Homburger advised BB Pureos Bioventures, LP in its investment in NovaGo Therapeutics AG's CHF 10 m Series A financing round to develop regenerative anti-Nogo therapy for stroke

April 2019. NovaGo Therapeutics AG (NovaGo), a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke, announced having closed a Series A financing round of CHF 10 m led by BB Pureos Bioventures, LP (Pureos) and strategic partner Neurimmune Holding AG (Neurimmune).

Pureos is a venture capital fund that exclusively invests in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats.

Homburger acted as legal advisor to Pureos in connection with its investment in NovaGo. The Homburger team was led by partner Dieter Gericke and included associate Nicola Togni and Mimoza Vejseli (all Corporate / M&A).